GSK PLC SP. ADR/2 NEW (GS70) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GSK PLC SP. ADR/2 NEW (GS70) has a cash flow conversion efficiency ratio of 0.065x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€1.14 Billion ≈ $1.33 Billion USD) by net assets (€17.42 Billion ≈ $20.37 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See GSK PLC SP. ADR/2 NEW (GS70) net asset quality to measure how much of total assets are equity-financed.
GSK PLC SP. ADR/2 NEW - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how GSK PLC SP. ADR/2 NEW's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of GSK PLC SP. ADR/2 NEW to evaluate the quality of earnings relative to operating cash generation.
GSK PLC SP. ADR/2 NEW Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GSK PLC SP. ADR/2 NEW ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
UBS Group AG
SW:UBSG
|
-0.043x |
|
GlaxoSmithKline plc
MX:GSKN
|
0.141x |
|
Pinduoduo Inc
F:9PDA
|
0.039x |
|
BNP Paribas SA
PA:BNP
|
0.004x |
|
State Bank of India
NSE:SBIN
|
-0.265x |
|
Air Liquide SA
PA:AI
|
0.130x |
|
CVS Health Corp
NYSE:CVS
|
0.045x |
|
Equinix Inc
NASDAQ:EQIX
|
0.050x |
Annual Cash Flow Conversion Efficiency for GSK PLC SP. ADR/2 NEW (2021–2025)
The table below shows the annual cash flow conversion efficiency of GSK PLC SP. ADR/2 NEW from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see GS70 company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €15.96 Billion ≈ $18.65 Billion |
€7.74 Billion ≈ $9.05 Billion |
0.485x | -3.13% |
| 2024-12-31 | €13.09 Billion ≈ $15.30 Billion |
€6.55 Billion ≈ $7.66 Billion |
0.501x | -5.32% |
| 2023-12-31 | €12.79 Billion ≈ $14.96 Billion |
€6.77 Billion ≈ $7.91 Billion |
0.529x | -27.86% |
| 2022-12-31 | €10.10 Billion ≈ $11.80 Billion |
€7.40 Billion ≈ $8.65 Billion |
0.733x | +96.80% |
| 2021-12-31 | €21.34 Billion ≈ $24.95 Billion |
€7.95 Billion ≈ $9.30 Billion |
0.373x | -- |
About GSK PLC SP. ADR/2 NEW
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more